## 1 Autoantibodies in COVID-19 correlate with anti-viral

# 2 humoral responses and distinct immune signatures

3

4 **Short title:** COVID-19: Autoantibodies correlate with humoral response

5

6 Patrick Taeschler<sup>1†</sup>, Carlo Cervia<sup>1†</sup>, Yves Zurbuchen<sup>1</sup>, Sara Hasler<sup>1</sup>, Christian Pou<sup>2</sup>, Ziyang

7 Tan<sup>2</sup>, Sarah Adamo<sup>1</sup>, Miro E. Raeber<sup>1</sup>, Esther Bächli<sup>3</sup>, Alain Rudiger<sup>4</sup>, Melina Stüssi-

8 Helbling<sup>5</sup>, Lars C. Huber<sup>5</sup>, Petter Brodin<sup>2,6,7</sup>, Jakob Nilsson<sup>1</sup>, Elsbeth Probst-Müller<sup>1</sup>, and Onur

- 9 Boyman<sup>1,8</sup> \*
- 10

<sup>1</sup>Department of Immunology, University Hospital Zurich, Zurich, Switzerland

- 12 <sup>2</sup> Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet,
- 13 Solna, Sweden
- 14 <sup>3</sup> Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland
- <sup>4</sup> Department of Medicine, Limmattal Hospital, Schlieren, Switzerland
- 16 <sup>5</sup> Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland
- <sup>6</sup> Pediatric Rheumatology, Karolinska University Hospital, Solna, Sweden

18 <sup>7</sup> Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

- <sup>8</sup> Faculty of Medicine, University of Zurich, Zurich, Switzerland
- <sup>†</sup>Contributed equally
- 21

22 \* Corresponding author: Onur Boyman, MD, Department of Immunology, University Hospital

- 23 Zurich, Schmelzbergstrasse 26, 8091 Zurich, Switzerland. E-mail: <u>onur.boyman@uzh.ch;</u>
- 24 phone: +41 44 255 2069.
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

## 27 Acknowledgements

28 This work was funded by Swiss National Science Foundation grants 310030-172978 and 29 310030-200669 (to OB), 4078P0-198431 (to OB and JN) and NRP78 Implementation 30 Programme (to CC and OB), Digitalization Initiative of the Zurich Higher Education 31 Institutions Rapid-Action Call #2021.1\_RAC\_ID\_34 (to CC), Swiss Academy of Medical 32 Sciences grants 323530-191220 (to CC), 323530-191230 (to YZ) and 323530-177975 (to SA), 33 Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in 34 Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of 35 36 Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB), 37 and an Innovation Grant of University Hospital Zurich (to OB). We thank the diagnostic 38 laboratories of the University Hospital Zurich, Alessandra Guaita, Claudia Meloni, Jennifer 39 Jörger, Jana Epprecht and Claudia Bachmann for their support, and the members of the 40 Boyman Laboratory for helpful discussions. The study overview graphic was generated with 41 BioRender.com.

## 43 Abstract

#### 44 Background

45 Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with 46 possible implications for disease course, immunity, and autoimmune pathology. In this study, 47 we longitudinally screened for clinically relevant systemic autoantibodies to assess their 48 prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of 49 COVID-19.

#### 50 Methods

We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19 patients followed-up to one year after infection, eleven vaccinated individuals, and 41 unexposed controls.

#### 56 **Results**

57 Compared to healthy controls, similar prevalence and patterns of ANA were present in patients 58 during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of 59 patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore, patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease. 60 61 These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific 62 antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody production to increased antigen-specific humoral responses. Notably, the qualitative breadth of 63 64 antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-65 negative individuals during acute COVID-19. In autoantibody-positive patients,

66	multiparametric characterization demonstrated an inflammatory signature during acute
67	COVID-19 and alterations of the B cell compartment after recovery.
68	Conclusion
69	Highly sensitive indirect immunofluorescence assays revealed transient autoantibody
70	production during acute SARS-CoV-2 infection, while the presence of autoantibodies in
71	COVID-19 patients correlated with increased anti-viral humoral immune responses and
72	inflammatory immune signatures.
73	
74	Word count: 245
75	Max word count: 250
76	
77	
78	
79	Keywords: Autoantibodies, Anti-nuclear antibodies, COVID-19, SARS-CoV-2, VirScan

## 81 Introduction

Acute coronavirus disease 19 (COVID-19) causes a large clinical spectrum, ranging from a 82 mild condition in the majority of cases to fatal disease in 1-2% of subjects.<sup>1-3</sup> Several features 83 84 of acute COVID-19 resemble clinical manifestations of systemic inflammatory and 85 autoimmune diseases, such as fatigue, myalgia, hyperinflammation, thrombosis, and skin rashes.<sup>3,4</sup> Furthermore, COVID-19 may trigger the onset of autoimmune pathology, as reported 86 87 for Guillain-Barré syndrome, anti-phospholipid syndrome, vasculitis, and multisystem inflammatory syndrome in children.<sup>5-9</sup> Vice versa, autoimmune phenomena have been 88 89 connected to the pathogenesis of severe COVID-19. Pre-existing autoantibodies targeting the 90 type I interferon pathway have been found in about 10% of COVID-19 cases with critical disease.10-12 91

92 Other acute or chronic viral infections have been associated with autoimmune responses, which have been proposed to arise by molecular mimicry, epitope spreading or bystander activation.<sup>13</sup> 93 94 Various autoantibodies have been described in association with COVID-19, including antinuclear antibodies (ANA),<sup>14-20</sup> anti-neutrophil cytoplasmic antibodies (ANCA),<sup>15,16,21</sup> anti-95 96 phospholipid antibodies, 5,8,14,17,19,22 and antibodies targeting different extracellular antigens.<sup>11,16</sup> While the presence of different autoantibodies has been associated with severe 97 COVID-19 and worse outcome,<sup>11,15,17-19</sup> it remains unclear to what extent autoantibodies are 98 99 triggered by acute infection, even though transient autoreactivity and new development of autoantibodies have been suggested in a subgroup of COVID-19 patients.<sup>16,20</sup> Furthermore, 100 101 several aspects of autoantibodies in COVID-19, including their interplay with virus-specific 102 humoral responses and their durability after acute infection, need further elucidation. In this 103 study, we comprehensively characterized autoantibodies by using highly sensitive indirect 104 immunofluorescence (IIF) assays in a multicentric prospective cohort of 227 individuals.

## 106 **Results**

#### 107 **Presence of systemic autoantibodies during acute COVID-19 and recovery**

108 We performed a comprehensive immunological characterization of 175 individuals with 109 confirmed COVID-19 up to one year after infection (Fig. 1A and Table 1, Table S1), including 110 autoantibody screening by IIF, serum proteomics and serological profiling. 41 individuals with 111 negative history and serology for severe acute respiratory syndrome coronavirus 2 (SARS-112 CoV-2) infection were included as controls (Fig. 1A and Table 1). Furthermore, eleven 113 unexposed individuals were sampled before and after vaccination with BNT162b2 (Table S2). 114 Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41 115 (41.4%) healthy individuals thus testing positive for ANA (Fig. 1B). This prevalence of ANA 116 positivity was similar to that in COVID-19 patients during acute disease (48.0%, odds ratio 117 (OR) = 1.30, p = 0.49) as well as six months (47.4%, OR = 1.27, p = 0.59) and one year after 118 recovery (42.3%, OR = 1.04, p = 1) (Fig. 1C–E). Most of the observed ANA titers were just 119 above the positivity threshold of 1:320. Interestingly, we observed a trend of higher ANA 120 prevalence in individuals with severe COVID-19 compared to mild disease during acute 121 infection (OR 1.85, p = 0.061), which was significantly higher at six months after recovery 122 (OR = 3.81, p = 0.0015) (**Fig. 1C** and **D**).

Similarly, we used an IIF assay to detect ANCA. ANCA prevalence was similar in mild COVID-19 patients during acute disease (3.6%) compared to healthy individuals (2.4%) (**Fig. 1F** and **G**). Conversely, we observed a significantly higher ANCA prevalence in severe acute COVID-19 patients (19.7%), both compared to healthy subjects (p = 0.0082) and mild COVID-19 cases (p = 0.0096) (**Fig. 1F** and **G**), which returned to ranges seen in healthy individuals after six months (5.1%, p = 0.61) and one year (14.3%, p = 0.15) (**Fig. 1H** and **I**).

- 129 In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently,
- 130 particularly during acute COVID-19 (Fig. 1J–M). Moreover, ANCA showed a tendency to be

more frequent in ANA-positive (14.3%) compared to ANA-negative (5.5%) individuals during acute COVID-19 (p = 0.06) (**Fig. 1K**).

133

## 134 Characteristics of ANA and ANCA patterns in acute COVID-19

To gain a qualitative appreciation, we classified ANA patterns according to the international consensus on ANA patterns anti-cell (AC) nomenclature.<sup>23</sup> ANA patterns were very similar in healthy controls and COVID-19 patients at all three sampling timepoints, and in some participants different patterns were detected concurrently (**Fig. 2A–D, Fig. S1A–D**). The most common nuclear patterns were fine-granular nuclear (AC-4 or AC-4 like) and nucleolar (AC-8, AC-9, and AC-10), whereas the most common cytoplasmic patterns were speckled (AC-19 and AC-20) (**Fig. 2E–G**).

142 ANCA patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic

(Fig. 2H). However, cytoplasmic patterns were atypical and, accordingly, none of the ANCApositive patients showed positivity for either anti-myeloperoxidase (MPO) or anti-proteinase 3
(PR3) antibodies (Fig. 2I), suggesting other antigen specificities than commonly found in
ANCA-associated vasculitis <sup>24,25</sup>.

147

#### 148 Temporal trajectory of autoantibodies in individual COVID-19 patients

To appreciate changes in ANA and ANCA on an individual level, we performed paired analysis of all followed-up COVID-19 patients (n = 129). For mild and severe COVID-19 patients combined, we observed similar proportions of patients with isolated ANA positivity during acute disease (14.7%) and follow-up (12.4%). However, a trend toward a higher proportion of new ANA development at follow-up visit was evident in patients with severe COVID-19 (20.5%) compared to patients with mild COVID-19 (8.2%) (OR = 2.84, p = 0.054) (**Fig. 3A** and **B**). To also account for subtle changes of IIF patterns, we conducted a blinded, paired

analysis of IIF images to identify patterns that were transiently present either during acute disease or follow-up. Strikingly, we found transient patterns in 11 of 62 (17.7%) ANA-positive COVID-19 patients during acute disease, with speckled cytoplasmic (AC-19 and 20), nucleolar (AC-8, 9, 10) and mitotic being the most frequent patterns (**Fig. 3C** and **D**). In stark contrast, only three of 59 (5.1%) ANA-positive individuals presented with a pattern during follow-up that was not present during acute disease, thus demonstrating that transient ANA patterns were significantly more prevalent during acute COVID-19 (p = 0.045) (**Fig. 3C**).

For ANCA, we observed that of ten patients that tested positive during acute COVID-19, eight were negative during follow-up, whereas only two remained positive. Furthermore, only one patient newly exhibited positive ANCA at follow-up (**Fig. 3E** and **F**). Collectively, we found that a subgroup of individuals shows ANA and atypical ANCA production during the acute phase of COVID-19, which usually subsides during follow-up.

168

## 169 Virus-specific responses in autoantibody-positive and SARS-CoV-2-vaccinated subjects

170 To elucidate the influence of autoantibody production during acute infection, we investigated 171 the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2. 172 We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA) and 173 IgG titers and found that presence of ANA was associated with higher concentrations of S1-174 specific antibodies in COVID-19 patients during acute disease, which extended to six months 175 after recovery (Fig. 4A). Conversely, one year after recovery, we did not observe any 176 differences (Fig. S2). The presence of ANA correlated significantly with S1-specific IgG levels 177 even after accounting for age, disease severity, and sampling timepoint in a multiple linear 178 regression model, which was not the case of S1-specific IgA (Fig. 4B, Table S3). Similarly, 179 we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested 180 positive for ANCA during acute disease (Fig. 4C).

181 To elucidate whether autoantibodies were associated with an increased humoral immune 182 response only after natural SARS-CoV-2 infection or also after other antigen-specific immune responses, we measured ANA and S1-specific antibodies in 11 individuals before and after 183 184 COVID-19 vaccination with BNT162b2 (Fig. 4D-F, Table S2). Although a tendency of an increased ANA prevalence following the first vaccine shot was apparent, no significant 185 difference was observed between sampling timepoints (Fig. 4D). We observed higher S1-186 187 specific IgA in ANA-positive individuals when combining data from two and four weeks after 188 the first vaccine shot, whereas no difference was observed for IgG (Fig. 4E and F). In summary, 189 these findings suggest the presence of autoantibodies is associated with increased S1-specific 190 humoral responses following acute COVID-19 up to six months after recovery and following 191 SARS-CoV-2 vaccination.

192

#### 193 Human virome-wide serological profiling in acute COVID-19

194 Next, we sought to investigate qualitative aspects of antibody responses during acute COVID-195 19 with respect to previous anti-viral humoral responses in ANA-positive and ANA-negative 196 individuals. Based on the phage immunoprecipitation sequencing (PhIP-seq) technology (VirScan),<sup>26</sup> we performed human virome-wide serological profiling in 97 acute COVID-19 197 198 patients and 18 healthy controls. We assessed the results of antibodies directed to 112 different 199 viruses (Table S4), with data for a total of 87,890 epitopes, consisting of 56-amino acid (AA)-200 long, overlapping peptides. The library comprised all six human coronaviruses (HCoV) 201 described before the COVID-19 pandemic, including HCoV-HKU1, HCoV-NL63, HCoV-202 229E, betacoronavirus 1 (BCoV1, including HCoV-OC43), severe acute respiratory syndrome-203 related coronavirus (SARS-CoV), and Middle east respiratory syndrome-related coronavirus 204 (MERS-CoV).

205 A multivariate analysis using the summed epitope hits per viral species revealed distinct 206 differences in COVID-19 patients compared to healthy controls, which were particularly 207 pronounced more than one week after symptom onset (Fig. 5A). Between-group comparisons 208 of COVID-19 patients and healthy controls revealed a significant difference (p < 0.005) of 209 summed epitope hits for eight viral species (Fig. 5B). Of these, four enterovirus species were 210 more abundant in healthy controls. Conversely, antibodies targeting cytomegalovirus (CMV) 211 and Pegivirus A, and those directed to SARS-CoV and MERS-CoV were significantly more 212 abundant in COVID-19 patients, whereas antibodies targeting the four common coronaviruses 213 HCoV-HKU1, HCoV-NL63, HCoV-229E, and BCoV1, showed a parallel, but insignificant 214 trend (p > 0.005) (Fig. 5B). Antibodies directed to all coronavirus species correlated positively 215 with time from symptom onset (Fig. 5C), thus indicating production of cross-reactive 216 antibodies during acute COVID-19.

217 To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological 218 profiles on a singular epitope level. We found a significantly higher (p < 0.05) proportion of 219 COVID-19 patients tested positive for a total of 18 CoV epitopes compared to healthy controls, 220 of which 16 were in the spike and two in the nucleoprotein (Fig. 5D, Fig. S3A). Since healthy 221 individuals tested negative for these but positive for only one epitope (Fig. 5D and E), we hypothesized these 18 CoV epitopes enriched in COVID-19 patients were targeted by 222 223 antibodies newly produced during acute COVID-19 and cross-reactive with shared epitopes of 224 other CoVs. Pairwise protein alignment of these epitopes with corresponding SARS-CoV-2 225 proteins allowed identification of regions of SARS-CoV-2 spike and nucleoprotein targeted by 226 cross-reactive antibodies, comprising two segments (AA positions 777–886 and 1105–1195) of spike S2 domain and one segment of nucleoprotein (AA 140-252), which have been 227 previously identified in COVID-19 patients <sup>27</sup>. Patients with severe COVID-19 tested positive 228 229 for significantly more cross-reactive antibodies than mild disease patients (Fig. 5E). However,

no significant difference was observed in ANA-positive compared to ANA-negative patients
(Fig. 5F), although the proportion of ANA-positive patients that tested positive was slightly
higher for most cross-reactive epitopes (Fig. 5G).

233 To explore potential correlations of ANA with humoral responses against other viruses, we 234 compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes 235 were detected more frequently (p < 0.005) in ANA-positive, but not in ANA-negative, 236 individuals (Fig. 5H). Three of the identified peptides were located on Epstein-Barr virus 237 (EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope 238 hits, independent of age (Fig. S3B). When combining data of all available epitopes, we found 239 significantly more hits in ANA-positive compared to ANA-negative participants, which was 240 most pronounced at younger age (Fig. 5I). Thus, human virome-wide serological profiling in 241 acute COVID-19 revealed antibodies cross-reactive to other coronaviruses, whereas ANA-242 positive participants producing antibodies to more viral epitopes on a virome wide level.

243

## 244 Association of autoantibodies with inflammatory signature during acute COVID-19

Several studies have associated autoantibodies with severe COVID-19.11,15,17-19 Thus, we 245 sought to further characterize ANA-positive and ANA-negative COVID-19 patients during 246 247 acute disease by proteomics comprising 86 inflammatory markers, cytokine measurements, 248 flow cytometry, clinical history, and routine diagnostic analyses. The proportion of participants 249 with a known autoimmune disease was low in our cohort and indifferent in individuals with or 250 without ANA or ANCA (Table 2). We found a higher prevalence of comorbidities in 251 autoantibody-positive patients, including hypertension and heart disease, but no significant sex 252 difference (Table 2).

A multivariate analysis with 130 variables, including demographic parameters, routine diagnostic measurements, and inflammation markers obtained by proteomics (**Table S5**),

255 allowed for a nearly complete separation of severe COVID-19 patients from healthy 256 individuals, with mild COVID-19 patients exhibiting intermediate characteristics (Fig. 6A). Several markers contributing to severe COVID-19 were significantly higher (p < 0.05) in 257 258 ANA-positive than ANA-negative COVID-19 patients, revealing an inflammatory signature 259 associated with severe disease in ANA-positive individuals (Fig. 6B). Importantly, ANA-260 positive COVID-19 patients were older and experienced longer hospitalization (Fig. 6C), and 261 many inflammation markers, including C-reactive protein (CRP) and interleukin (IL)-6, were 262 elevated compared to ANA-negative patients (Fig. 6D). Furthermore, ANA-positivity was 263 associated with T cell activation as suggested by higher soluble IL-2 receptor alpha (sIL-2R $\alpha$ ) serum concentrations and increased proportions of activated CD38<sup>+</sup> HLA-DR<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> 264 T cells (Fig. 6E). Similar trends toward an inflammatory signature were also observed in 265 266 ANCA-positive individuals during acute COVID-19, although these results were limited due 267 to lower prevalence of ANCA (Fig. S4A and B).

Finally, we assessed characteristics of ANA-positive and ANA-negative COVID-19 patients 268 269 at six months after acute disease to identify alterations in the absence of acute inflammation. A 270 multivariate analysis of 43 parameters, including patient characteristics and routine diagnostic 271 measurements, revealed differences comparing ANA-positive and ANA-negative individuals, 272 with several inflammation markers, including IL-6, tumor necrosis factor alpha (TNF- $\alpha$ ), and 273 sIL-2Ra, being significantly higher in ANA-positive participants (Fig. 6F and G, Table S6). 274 Interestingly, we also observed differences in Ig subclasses, with significantly higher IgG1 and 275 significantly lower IgM in ANA-positive individuals (Fig. 6H). Furthermore, marked changes 276 in B cell subsets were apparent, with higher frequencies of IgD<sup>+</sup> CD27<sup>-</sup> naïve B cells and lower 277 frequencies of IgD<sup>+</sup> CD27<sup>+</sup> non-switched and IgD<sup>-</sup> CD27<sup>+</sup> switched memory B cells in ANA-278 positive individuals (Fig. 6I). Altogether, in autoantibody-positive COVID-19 patients, we 279 found an inflammatory signature during acute disease resembling alterations found in severe

- 280 disease and changes in inflammation markers, Ig subclasses, and B cells at six months after
- 281 recovery.

## 283 Discussion

Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following 284 viral infections have been well described,<sup>28,29</sup> their significance has remained ill-defined. In 285 286 this study, we used highly sensitive assays to detect ANA and ANCA, representing systemic 287 autoantibodies, in patients up to one year after infection with SARS-CoV-2. Firstly, we found 288 transient ANA and ANCA in a subgroup of participants during acute COVID-19. Autoantibody 289 production could result from activation of autoreactive B and T cells recognizing viral epitopes by means of molecular mimicry.<sup>30,31</sup> Alternatively, antigen-independent 'bystander' activation 290 291 of autoreactive B and T cells by cytokines and other inflammatory mediators could drive autoantibody production.<sup>32,33</sup> Particularly in severe COVID-19, which is associated with early 292 neutrophilia and pronounced neutrophil extracellular trap (NET) formation,<sup>34,35</sup> NETs expose 293 shielded intracellular self-antigens,<sup>25,36,37</sup> thus causing production of ANCA and ANA. 294 295 Interestingly, a high prevalence of IgA ANCA has been reported in acute COVID-19 patients showing chilblain-like lesions.<sup>21</sup> In our study, all ANCA-positive subjects tested negative for 296 anti-MPO and anti-PR3 antibodies, thus it remains elusive whether these ANCA have 297 298 pathogenic potential.

299 Secondly, we found distinct features in autoantibody-positive COVID-19 patients during acute 300 disease and recovery. Autoantibodies were associated with prolonged hospitalization and inflammation markers during acute disease, supporting recent findings.<sup>11,15,17-19,38,39</sup> Whereas 301 autoantibodies targeting type I interferons have been linked to severe COVID-19.<sup>10-12,16</sup> severe 302 303 COVID-19 could decrease self-tolerance by tissue damage and inflammation, altogether leading to generation of autoantibodies. However, confounding factors should be considered, 304 such as age and comorbidities, affecting prevalence of autoantibodies<sup>40</sup> and risk of severe 305 306 COVID-19<sup>1</sup>. Following these considerations, we found changes in ANA-positive individuals 307 even six months after acute COVID-19, indicating ongoing low-grade inflammation.

308 Furthermore, we observed alterations of the B cell compartment, including increased naïve and 309 decreased memory B cells, previously associated with pre-symptomatic and early-stage autoimmune diseases.<sup>41-43</sup> Differences in total Ig concentrations have been found in 310 autoimmune diseases<sup>44</sup> and patients suffering from post-acute COVID-19 syndrome (PACS)<sup>45</sup>. 311 312 Thus, we have previously identified an Ig signature in PACS, including low total IgM, and found clinical risk factors, including increased age and severe disease course.<sup>45</sup> Although a 313 314 direct link to autoantibody development in PACS has not been reported, a misdirected immune 315 response may underly both manifestations.

316 Thirdly, we observed higher S1-specific antibody titers in autoantibody-positive COVID-19 317 patients. Similarly, recent reports found increased anti-viral humoral responses in 318 autoantibody-positive individuals during acute COVID-19, although the interrelation remained unclear.<sup>16,19,22</sup> Interestingly, following COVID-19 mRNA vaccination in systemic lupus 319 320 erythematosus (SLE) patients, higher humoral responses positively correlated with antidsDNA antibodies,<sup>39</sup> supporting our findings of increased S1-specific IgA production in ANA-321 322 positive individuals following vaccination. These findings indicate an inherent capacity of 323 ANA-positive individuals to mount more robust antibody responses upon antigen challenge. 324 Human virome-wide serological profiling revealed production of cross-reactive antibodies to other coronaviruses during acute COVID-19, particularly in severe disease, consistent with 325 broader humoral immune responses in severe COVID-19.27 Whereas antibodies targeted 326 327 similar cross-reactive coronavirus epitopes in ANA-positive and ANA-negative COVID-19 328 patients, more antibodies targeted EBV antigen EBNA-2 in ANA-positive individuals. Higher 329 humoral responses against EBV have been described in ANA-positive individuals, irrespective of autoimmune disease.<sup>46,47</sup> Also, EBV has been associated with development of ANA and 330 SLE.<sup>48</sup> Furthermore, severe acute COVID-19 is characterized by extrafollicular B cell 331 activation,<sup>20,38,49</sup> which is found in autoimmune disease and associated with activation of 332

autoreactive B cells. This increased response could allow for rapid formation of virus-specific antibody-secreting cells,<sup>20</sup> potentially explaining why individuals with autoantibodies exhibit higher humoral responses during acute COVID-19. Whether autoantibody-positive subjects also show increased SARS-CoV-2-specific long-lived T cells responses<sup>50</sup> remains to be investigated.

Limitations of this study include the use of highly sensitive IIF assays that yielded a high prevalence of positive results in healthy subjects and COVID-19 patients. Most of the measured ANA titers were at or just above the threshold level, which usually would be considered of irrelevant clinical significance. Moreover, we did not assess the specificity of autoantibodies, but recent studies have shown reactivity to a wide spectrum of autoantigens.<sup>11,16</sup> Altogether, our study shows autoantibodies in COVID-19 appear to be transient and correlate

with increased anti-viral humoral immune responses and a distinct immune signature. As questions arise regarding long-term consequences of COVID-19, including the risk of immune dysregulation and autoimmune disease, understanding the mechanisms involved in balancing self-tolerance and protective immune responses become crucial to recognize and manage patients at risk for developing autoimmune diseases.

## 350 Methods

## 351 Human subjects and patient characteristics

352 Following written informed consent, adult individuals were recruited for medical history and

blood sampling between April 2020 and May 2021. The study was approved by the Cantonal

- Ethics Committee of Zurich (BASEC #2016-01440). The cohort comprised mild and severe
- 355 COVID-19 patients, healthy controls, and vaccinated individuals.
- 356 *COVID-19 patients* (**Table 1**, **Table S1**): 175 patients with reverse transcriptase quantitative 357 polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection were included 358 during acute COVID-19 at four hospitals in the Canton of Zurich, Switzerland. COVID-19 was

359 classified for maximum disease severity according to the World Health Organization (WHO)

360 classification criteria into mild disease – including asymptomatic (n = 4), mild illness (n = 93)

and mild pneumonia (n = 12) – and severe disease – including severe pneumonia (n = 30) and

acute respiratory distress syndrome (n = 36)  $^{51}$ . Follow-up visits for medical history and blood collection were conducted approximately six months and one year after symptom onset.

364 Unreachable individuals or those declining further participation were lost to follow-up.

365 *Healthy controls* (**Table 1**): 41 participants with negative history of SARS-CoV-2 infection 366 and serology were recruited. Five individuals developed COVID-19 after inclusion and were 367 subsequently allocated to the patient cohort.

*Vaccinated individuals* (Table S2): 11 individuals with a negative history and serology for
 SARS-CoV-2 infection were sampled once before vaccination, once after the first and twice
 after the second mRNA vaccination with BNT162b2 (BioNTech-Pfizer).

371

### 372 Autoantibody detection

ANA were measured by IIF on HEp-2 cells (Euroimmun) with a cut-off dilution of 1:320.
ANCA were measured by IIF on neutrophils fixed by ethanol and formalin (Euroimmun) with

a cut-off dilution of 1:40. IIF imaging was performed using a diagnostic, computer-aided
microscopy system (Euroimmun). ANA patterns were classified according to the international
consensus on ANA patterns anti-cell (AC) nomenclature<sup>23</sup> by blinded trained personnel. For
paired analyses of ANA patterns, 129 pairs of IIF pictures at 1:320 dilution were blinded for
patient characteristics and sampling timepoint, and examined pairwise by the same observer.
Antibodies against myeloperoxidase and proteinase 3 were measured on Phadia<sup>TM</sup> 250
(ThermoFisher Scientific) or on Bioflash<sup>®</sup> (Werfen) according to manufacturer's instructions.

## 383 Immunoassays

Immunoassays for Ig subsets, anti-SARS-CoV-2 spike S1-specific IgA and IgG, interleukin 384 (IL)-1β, IL-2, IL-5, IL-6, IL-10, IL-12, interferon-γ (IFN-γ), sIL-2Rα, and tumor necrosis 385 386 factor  $\alpha$  (TNF- $\alpha$ ), were performed in accredited laboratories at University Hospital Zurich. Serum Ig subsets were quantified on an Optilite<sup>®</sup> turbidimeter (The Binding Site Group). S1-387 388 specific IgA and IgG were measured by enzyme-linked immunosorbent assays (ELISA) (Euroimmun), as established <sup>52</sup>. IL-1 $\beta$ , IL-2, IL-6, IFN- $\gamma$  and sIL-2R $\alpha$  were determined by 389 ELISA (R&D Systems) on Opsys Reader<sup>TM</sup> (Dynex). IL-5, IL-10 and IL-12 were measured by 390 391 cytometric bead assays (BD Biosciences) on a Navios cytometer (Beckman Coulter). TNF-a was determined with a kit (R&D Systems) using MagPix<sup>®</sup> (ThermoFisher Scientific). 392

393

#### **Flow cytometry**

As established <sup>53</sup>, blood samples were processed and analyzed in accredited laboratories at University Hospital Zurich. Blood samples were lysed with VersaLyse, fixed with IOTest3 solution and stained with antibodies (Beckman Coulter; **Table S7**). Absolute cell counts were determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter).

## 400 Serum proteomics

401 Serum samples were analyzed by a proximity extension assay-based technology 92-plex 402 inflammation panel (Olink<sup>®</sup>), as established <sup>33,53,54</sup>. Six parameters were excluded because less 403 than 50% of samples showed results above detection limit.

404

## 405 Human virome-wide serological profiling

As established,<sup>7,55</sup> serum samples were inactivated, normalized for total IgG concentration, and 406 407 incubated as duplicates with a bacteriophage library displaying linear, 56 amino acid long viral 408 epitopes. IgG-phage complexes were captured with magnetic beads, lysed and quantified by 409 next-generation sequencing. Blank beads samples were used as negative controls. Reads were 410 mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools. A 411 previously described binning strategy was used to identify positivity for epitopes,<sup>56</sup> with a 412 minimum z-score of 3.5 for both sample replicates compared to negative controls. Results for 413 a total of 112 different human viruses were included in the further analysis. (Table S4), 414 whereas eukaryotes, prokaryotes, non-human viruses and human viruses with no variance or a 415 maximal summed epitope hit count below three were excluded.

416

#### 417 Statistics

418 Statistical analyses were performed using R (version 4.1.0). Unless otherwise specified, 419 between-group comparison was performed using two-tailed, non-parametric, unpaired testing 420 (Mann-Whitney U) for numeric variables and odds ratios with Fisher's exact test for categorical 421 variables, with p-values of <0.05 defined as significant. Missing values were omitted. Principal 422 component analyses (PCA) were performed using stats (4.2.0) and factoextra (1.0.7) with 423 scaled, centered variables, and loadings are shown as variable coordinates. Spearman's rank 424 correlation was used for associations of numeric variables. Pairwise protein alignment for 56-

425	amino acid (AA) long peptides with SARS-CoV-2 spike (Uniprot Entry P0DTC2) and
426	nucleoprotein (P0DTC9) was generated using Biostrings (2.60.2), with BLOSUM62
427	substitution matrix and gap opening and extension penalty of -11 and -1, respectively. Data
428	visualization was performed using ggplot2 (version 3.3.5), ggfortify (0.4.12), ggVennDiagram
429	(1.1.4), UpSetR (1.4.0), and corrplot (0.90). Horizontal lines in violin plots represent medians.
430	Regression lines represent simple linear regression models.
121	

431

432 Word count: 3840

## 434 Author contributions

- 435 P.T. contributed to patient recruitment and data collection, analysis and interpretation. C.C.
- 436 contributed to patient recruitment, data collection and data interpretation. Y.Z., S.H., and S.A.
- 437 contributed to patient recruitment and data collection. C.P., Z.T., and P.B. contributed to data
- 438 collection. M.E.R. contributed to patient recruitment and clinical management. E.B., A.R.,
- 439 M.S.-H., L.C.H., and J.N. contributed to patient recruitment. E.P.-M. contributed to data
- 440 analysis. O.B. conceived the project and interpreted the data. P.T. and O.B. wrote the
- 441 manuscript. All authors edited and approved the final draft of the article.
- 442

## 443 **Conflict of interest statement**

444 The authors declare no conflict of interest in relation to this work.

#### **References** 446

- 447 1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in 448 China. N Engl J Med. 2020;382(18):1708-1720.
- 449 2. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and 450 influenza pandemics. Lancet Infect Dis. 2020;20(9):e238-e244.
- 451 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, 3. 452 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A 453 Review. JAMA. 2020;324(8):782-793.
- 454 Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin 4. 455 Rheumatol. 2021;33(2):155-162.
- 456 5. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in 457 Patients with Covid-19. N Engl J Med. 2020;382(17):e38.
- 458 Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré Syndrome Associated with 6. 459 SARS-CoV-2. N Engl J Med. 2020;382(26):2574-2576.
- 460 Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem 7. 461 Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-462 981.e967.
- 463 8. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients 464 hospitalized with COVID-19. Sci Transl Med. 2020;12(570).
- 465 9. Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic 466 rheumatic disease following COVID-19. Lancet Rheumatol. 2021;3(6):e402-e404.
- 467 10. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients 468 with life-threatening COVID-19. Science. 2020;370(6515).
- Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with 469 11. 470 COVID-19. Nature. 2021;595(7866):283-288.
- 471 12. Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are 472 present in. Sci Immunol. 2021;6(62).
- 473 Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander 13. 474 activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 475 2006;19(1):80-94.
- 476 Vlachoviannopoulos PG, Magira E, Alexopoulos H, et al. Autoantibodies related to 14. 477 systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann 478 Rheum Dis. 2020;79(12):1661-1663.
- 479 Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of 15. 480 autoimmune response. Clin Transl Sci. 2021;14(3):898-907.
- 481 16. Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized 482 patients with COVID-19. Nat Commun. 2021;12(1):5417.
- 483 Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological 17. 484 Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021;14(2):502-508.
- 485 Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-18. 486 19. Clin Transl Sci. 2021.
- 487 Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of 19. 488 autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl 489 Autoimmun. 2020;3:100073.
- 490 20. Woodruff MC, Ramonell RP, Saini AS, et al. Relaxed peripheral tolerance drives broad. 491 medRxiv. 2021.
- 492 21. Frumholtz L, Bouaziz JD, Battistella M, et al. Type I interferon response and vascular 493 alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol. 2021.

- 494 22. Emmenegger M, Kumar SS, Emmenegger V, et al. Anti-prothrombin autoantibodies 495 enriched after infection with SARS-CoV-2 and influenced by strength of antibody 496 response against SARS-CoV-2 proteins. PLoS Pathog. 2021;17(12):e1010118.
- 497 23. Chan EK, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus 498 on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-499 2015. Front Immunol. 2015;6:412.
- 500 24. Suwanchote S, Rachayon M, Rodsaward P, et al. Anti-neutrophil cytoplasmic 501 antibodies and their clinical significance. Clin Rheumatol. 2018;37(4):875-884.
- 502 Nakazawa D, Kumar S, Desai J, Anders HJ. Neutrophil extracellular traps in tissue 25. 503 pathology. Histol Histopathol. 2017;32(3):203-213.
- 504 Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of 26. 505 human populations using a synthetic human virome. Science. 2015;348(6239):aaa0698.
- 506 27. Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients 507 reveals cross-reactivity and correlates of severity. Science. 2020;370(6520).
- 508 28. Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. Semin 509 Arthritis Rheum. 1998;27(5):263-271.
- 510 29. Spohn G, Arenas-Ramirez N, Bouchaud G, Boyman O. Endogenous polyclonal anti-IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation. J 511 512 Allergy Clin Immunol. 2017;139(6):1957-1965.e1953.
- 513 30. Moody R, Wilson KL, Boer JC, et al. Predicted B Cell Epitopes Highlight the Potential 514 for COVID-19 to Drive Self-Reactive Immunity. Frontiers in Bioinformatics. 515 2021;1(31).
- 516 31. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Jl Macario A, 517 Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. 518 Autoimmun Rev. 2020;19(8):102591.
- Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-2273. 519 32.
- 520 Chevrier S, Zurbuchen Y, Cervia C, et al. A distinct innate immune signature marks 33. 521 progression from mild to severe COVID-19. Cell Rep Med. 2021;2(1):100166.
- 522 34. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI 523 Insight. 2020;5(11).
- 524 Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front 35. 525 Immunol. 2021;12:652470.
- 526 van der Linden M, van den Hoogen LL, Westerlaken GHA, et al. Neutrophil 36. 527 extracellular trap release is associated with antinuclear antibodies in systemic lupus 528 erythematosus and anti-phospholipid syndrome. *Rheumatology* (Oxford). 529 2018;57(7):1228-1234.
- 530 Egholm C, Heeb LEM, Impellizzieri D, Boyman O. The Regulatory Effects of 37. 531 Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses. Front 532 Immunol. 2019;10:2507.
- 533 38. Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses 534 correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 535 2020;21(12):1506-1516.
- 536 Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of Immune Response and 39. 537 Disease Status in SLE Patients Following SARS-CoV-2 Vaccination. Arthritis 538 Rheumatol. 2021.
- 539 40. Dinse GE, Parks CG, Weinberg CR, et al. Increasing Prevalence of Antinuclear 540 Antibodies in the United States. Arthritis Rheumatol. 2020;72(6):1026-1035.
- 541 41. Baglaenko Y, Chang NH, Johnson SR, et al. The presence of anti-nuclear antibodies 542 alone is associated with changes in B cell activation and T follicular helper cells similar

543		to those in systemic autoimmune rheumatic disease. Arthritis Res Ther.
544		2018;20(1):264.
545	42.	Zhu L, Yin Z, Ju B, et al. Altered frequencies of memory B cells in new-onset systemic
546		lupus erythematosus patients. <i>Clin Rheumatol</i> . 2018;37(1):205-212.
547	43.	Slight-Webb S, Lu R, Ritterhouse LL, et al. Autoantibody-Positive Healthy Individuals
548		Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis
549		Rheumatol. 2016;68(10):2492-2502.
550	44.	Zhang H, Li P, Wu D, et al. Serum IgG subclasses in autoimmune diseases. Medicine
551		(Baltimore). 2015;94(2):e387.
552	45.	Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of
553		post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446.
554	46.	Slight-Webb S, Smith M, Bylinska A, et al. Autoantibody-positive healthy individuals
555		with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol.
556		2020;146(6):1419-1433.
557	47.	Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological
558		reactivation with transitioning to systemic lupus erythematosus in at-risk individuals.
559		Ann Rheum Dis. 2019;78(9):1235-1241.
560	48.	Cuomo L, Cirone M, Di Gregorio AO, et al. Elevated antinuclear antibodies and altered
561		anti-Epstein-Barr virus immune responses, Virus Res. 2015:195:95-99.
562	49.	Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-Expressing T Follicular Helper Cells
563		and Germinal Centers in COVID-19. <i>Cell</i> , 2020;183(1):143-157.e113.
564	50.	Adamo S. Michler J. Zurbuchen Y. et al. Signature of long-lived memory CD8. <i>Nature</i> .
565	001	2021.
566	51.	WHO, COVID-19 Clinical management: living guidance. World Health Organization
567	011	(2021) doi: www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 In
568	52	Cervia C. Nilsson J. Zurbuchen Y. et al. Systemic and mucosal antibody responses
569	0	specific to SARS-CoV-2 during mild versus severe COVID-19 <i>J Allergy Clin</i>
570		Immunol 2021:147(2):545-557 e549
571	53	Adamo S Chevrier S Cervia C et al Profound dysregulation of T cell homeostasis
572	001	and function in patients with severe COVID-19 Allergy 2021:76(9):2866-2881
573	54	Lundherg M Friksson A Tran B Assarsson F. Fredriksson S. Homogeneous antibody-
574	511	hased proximity extension assays provide sensitive and specific detection of low-
575		abundant proteins in human blood <i>Nucleic Acids Res</i> 2011:39(15):e102
576	55	Pou C Nkulikivimfura D Henckel F et al The repertoire of maternal anti-viral
570	55.	antibodies in human newborns Nat Mad 2019:25(1):501-596
578	56	Ming MI Kulg T Long V et al Megeles virus infection diminishes preevisting
570	50.	antibodies that offer protection from other pathogens. Science, 2010:366(6465):509
580		606
500		000.
201		

		Healthy controls	COVID-19		COVID-19	
			Acute	disease	6-month follow-up	
	Disease severity		Mild Severe		Mild	Severe
	n (%)	41	109 (62.3%)	66 (37.7%)	77 (66.3%)	39 (33.7%)
Patient	Age	32 (28–52)	34 (28–52)	68 (57–78)	36 (29–53)	64 (58–74)
characteristics	Days after symptom onset		10 (7–16)	14 (9–27)	194 (185–205)	211 (194–224)
	Sex (female)	24 (58.5%)	54 (49.5%)	27 (40.9%)	40 (51.3%)	14 (35.9%)
	Vaccinated	0	0	0	9 (11.7%)	3 (7.7%)
	Hospitalized	-	20 (18.3%)	66 (100%)	12 (15.6%)	39 (100%)
Laboratory	Lymphocyte count (G/l)	1.80 (1.48–2.33)	1.81 (1.18–2.23) ns	0.76 (0.56–1.10)****	1.96 (1.67–2.37) ns	1.77 (1.48–2.34) ns
parameters	CRP (mg/l)	0.6 (0.4–1.6)	1.3 (0.6–5.3)**	59.2 (32.2–119.0)****	0.6 (0.6–1.3) ns	1.7 (2.2–5.1)**
	TNF-α (ng/l)	8.1 (6.4–10.0)	9.8 (7.6–12)**	16.4 (13.0–20.6)****	9 (6.8–10.9) ns	11.8 (9.3–15.0)****
	IL-6 (ng/l)	0.5 (0-1.1)	1.3 (0.1–4.9)***	19.5 (7.4–57.0)****	0.9 (0-2.1)*	1.6 (0.3–5.3)**
	S1-specific IgA (OD ratio)	0.33 (0.25-0.46)	1.77 (0.73–4.81)****	7.24 (2.52–10.2)****	2.52 (1.54-4.96)****	5.09 (3.12–7.75)****
	S1-specific IgG (OD ratio)	0.20 (0.17-0.25)	0.61 (0.27-2.19)****	5.12 (0.32–9.33)****	2.67 (1.29–5.69)****	6.91 (5.18-8.49)****
Comorbidities	Hypertension (n)	5 (12.2%)	12 (11.0%) ns	38 (57.8%)***	6 (7.8%) ns	21 (53.8%)**
	Diabetes (n)	2 (4.9%)	6 (5.5%) ns	19 (28.8%)*	4 (5.2%) ns	12 (30.7%)**
	Heart disease (n)	1 (2.4%)	6 (5.5%) ns	24 (36.6%)***	2 (2.6%) ns	15 (38.5%)***
	Lung disease (n)	5 (12.2%)	10 (9.2%) ns	12 (18.8%)*	5 (6.5%) ns	11 (28.2%) ns
	Malignancy (n)	1 (2.4%)	3 (2.8%) ns	8 (12.1%)**	3 (3.9%) ns	5 (12.8%) ns
	Kidney disease (n)	0 (0%)	8 (7.3%) ns	17 (25.8%)***	3 (3.9%) ns	10 (25.6%)**
	Autoimmune disease (n)	3 (7.3%)	6 (5.5%) ns	7 (10.6%) ns	6 (7.8%) ns	6 (15.4%) ns

## 582 Table 1. COVID-19 study cohort characteristics.

583 Medians and interquartile ranges (in parentheses) are specified for continuous variables, with p-values obtained by Mann-Whitney U test, compared

to healthy individuals. Numbers of individuals (n) and percentages of corresponding subgroup (in parentheses) are shown for categorical variables, with p-values calculated by Fisher's exact test, in comparison to healthy individuals. ns, non-significant; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001;

586 \*\*\*\*, p < 0.0001. OD, optical density.

			COVID-19			COVID-19	
			Acute disease		(	6-month follow-up	
ANA		ANA-negative	ANA-positive	p-value	ANA-negative	ANA-positive	p-value
Patient characteristics	n (%)	91 (52.0%)	84 (48.0%)	_	61 (52.6%)	55 (47.4%)	-
	Age	38 (30–58)	60.5 (38–73)	***	33(29-47)	61 (45–69)	****
	Days after symptom onset	11 (7–16)	12 (7–19)	ns	195 (186–206)	204 (183–218)	ns
	Sex (female)	43 (47.3%)	38 (45.2%)	OR 0.92, ns	29 (47.5%)	25 (45.5%)	OR 0.95, ns
Comorbidities	Hypertension	18 (19.7%)	32 (38.1%)	OR 2.48, *	8 (12.1%)	19 (34.5%)	OR 3.39, **
	Diabetes mellitus	12 (13.2%)	13 (15.5%)	OR 1.20, ns	6 (9.8%)	10 (18.2%)	OR 1.99, ns
	Heart disease	9 (9.9%)	21 (25.0%)	OR 3.02, **	1 (1.6%)	16 (29.1%)	OR 23.68, ***
	Lung disease	15 (16.5%)	7 (8.3%)	OR 0.46, ns	9 (14.8%)	7 (12.7%)	OR 0.87, ns
	Kidney disease	11 (12.1%)	14 (16.7%)	OR 1.45, ns	2 (3.3%)	11 (20.0%)	OR 7.14, **
	Malignancy	4 (4.4%)	8 (9.5%)	OR 2.28, ns	4 (6.6%)	5 (9.1%)	OR 1.40, ns
	Autoimmune disease	8 (8.7%)	5 (5.9%)	OR 0.66, ns	5 (8.2%)	7 (12.7%)	OR 1.62, ns
ANCA		ANCA-negative	ANCA-positive	p-value	ANCA-negative	ANCA-positive	p-value
Patient characteristics	n (%)	158 (90.3%)	17 (9.7%)	_	113 (97.4%)	3 (2.6%)	_
	Age	44 (32–65)	71 (57–80)	***	43 (31–64)	69 (64–70)	_
	Days after symptom onset	11 (7–16)	11 (9–19)	ns	199 (187–216)	182 (164–212)	-
	Sex (female)	74 (46.8%)	7 (41.2%)	OR 0.79, ns	52 (46.0%)	1 (33.3%)	_
Comorbidities	Hypertension	41 (25.9%)	9 (52.4%)	OR 3.19, *	27 (23.9%)	0 (0%)	-
	Diabetes mellitus	21 (13.2%)	4 (23.5%)	OR 2.00, ns	15 (13.3%)	1 (33.3%)	_
	Heart disease	24 (15.2%)	6 (35.2%)	OR 3.02, ns	16 (14.2%)	1 (33.3%)	_
	Lung disease	21 (13.3%)	1 (5.9%)	OR 0.41, ns	15 (13.3%)	1 (33.3%)	_
	Kidney disease	22 (13.9%)	3 (17.6%)	OR 1.32, ns	12 (10.6%)	1 (33.3%)	_
	Malignancy	10 (5.9%)	2 (11.8%)	OR 1.96, ns	8 (7.1%)	1 (33.3%)	_
	Autoimmune disease	12 (7.6%)	1 (5.9%)	OR 0.76, ns	12 (10.6%)	1 (33.3%)	-

588 Table 2. Characteristics of ANA- or ANCA-positive and -negative COVID-19 patients at acute disease or six months after infection.

589 For continuous variables, medians and interquartile ranges (in parentheses) are specified, with p-values obtained by Mann-Whitney U test

590 comparing individuals with and without autoantibodies. For categorical variables, numbers of individuals (n) and percentages of the

591 corresponding subgroup (in parentheses) and odds ratios (OR) with p-values indicating significance in Fisher's exact test are shown. ns, non-

592 significant; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001.

## 593 **Figure legends**

- 594 Figure 1. Prevalence of autoantibodies in healthy controls and COVID-19 patients during
- 595 acute disease and follow-up. (A) Study overview. (B–I) Prevalence of ANA titers (B-E) and
- 596 ANCA (F-I) in healthy controls (n = 41) and COVID-19 patients during acute disease (n = 41)
- 597 175), six months (n = 116) and one year (n = 92) after symptom onset. (J–M) Venn diagrams
- 598 depicting co-occurrence of nuclear ANA, cytoplasmic ANA and ANCA in healthy individuals
- 599 (J; n = 17), acute COVID-19 patients (K; n = 89) and COVID-19 patients six months (L; n =
- 600 56) or one year (M; n = 42) after SARS-CoV-2 infection that presented with at least one type
- 601 of autoantibody. P-values indicate comparison of ANA (B-E) and ANCA (F-I) prevalence
- 602 between mild and severe COVID-19 patients using Fisher's exact test.

## 603 Figure 2. IIF pattern of autoantibodies in acute and recovered COVID-19. (A-D)

- 604 Intersection plots showing counts of the four most prevalent ANA patterns (horizontal bars)
- and counts of pattern combinations (vertical bars) as indicated by the dot matrix, for healthy
- 606 controls (A), and COVID-19 patients during acute disease (B), six months (C) and one year
- 607 after symptom onset (D). (E–G) Example IIF pictures showing the most common nuclear,
- 608 including fine-granular (E) and nucleolar (F), and cytoplasmic, including speckled (G), ANA
- 609 patterns observed in the study cohort. All images were recorded at a dilution of 1:320. y/o,
- 610 years old. (H) IIF ANCA patterns observed in ANCA-positive COVID-19 patients during acute
- 611 disease (n = 17) and six months after recovery (n = 3). (I) Anti-MPO and anti-PR3 antibodies
- 612 during acute COVID-19 (n = 175) in ANCA-positive and ANCA-negative individuals. Dashed
- 613 lines indicate diagnostic cut-off values.

## 614 Figure 3. Paired longitudinal comparison indicates transient induction of autoantibodies

- 615 in acute COVID-19. (A–B) Temporal trajectory of ANA titers in mild (A, n = 85) and severe
- (B, n = 44) COVID-19 patients, showing the first available follow-up sample, i.e. at six months
- (n = 116) or one year (n = 13) after symptom onset. Colors indicate development of ANA status
- 618 from acute disease to follow-up. (C) Results from blinded, paired IIF picture analysis (n = 129).
- 619 Patterns that were uniquely observed at one timepoint are colored. (D) Exemplary IIF pictures
- 620 of three patients exhibiting transient ANA patterns during acute COVID-19, with a transient
- 621 nucleolar (left), cytoplasmic (middle), or mitotic (right) pattern. All pictures were recorded at
- 622 a dilution of 1:320. y/o, years old. (E-F) Temporal trajectory of ANCA titers in mild (E, n =
- 623 85) and severe (F, n = 44) COVID-19 patients. Colors indicate development of ANCA status
- from acute disease to follow-up.

625	Figure 4. Presence of autoantibodies is associated with an increased virus-specific
626	humoral response after SARS-CoV-2 infection and vaccination. (A–B) S1-specific IgA and
627	IgG in ANA-positive and ANA-negative COVID-19 patients during acute disease (n = 175)
628	and six months after recovery $(n = 104)$ . (B) P-values indicate significance of the correlation
629	of ANA positivity as an independent parameter in a multiple linear regression model
630	accounting for age, disease severity and sampling timepoint (Table S3). (C) S1-specific IgA
631	and IgG in ANCA-positive and ANCA-negative COVID-19 patients during acute disease (n =
632	175). ( <b>D</b> ) ANA prevalence and titers in previously unexposed individuals ( $n = 11$ ) before and
633	after vaccination with BNT162b2 at indicated timepoints. The p-value was calculated using
634	Chi-squared test of independence. (E) S1-specific IgA and IgG before and after COVID19
635	vaccination ( $n = 11$ ). Red vertical lines indicate the timepoints of first and second vaccination
636	with BNT162b2. (F) S1-specific IgA and IgG in ANA-positive and ANA-negative participants
637	following COVID-19 vaccination with BNT162b2, combining data from 10-13d after the first
638	(n = 11) and 1-3d after the second $(n = 10)$ vaccination.

# Figure 5. Comprehensive serological profiling (VirScan) in ANA-positive and ANAnegative individuals during acute COVID-19. (A) Principal component analysis (PCA) of 112 viral species, including data of 18 healthy individuals and 96 acute COVID-19 patients,

642 grouped by timepoint of sample collection after symptom onset. Each dot represents an 643 individual participant. (B) Loadings of PCA depicted in (A), with each viral species shown as individual dots (Table S4). Colors indicate participant groups with higher mean epitope hits 644 645 per species. Viral species with significant difference (p < 0.005) between COVID-19 patients and healthy controls are shown as large colored dots. Black crosses indicate insignificant 646 647 differences of coronaviruses (p > 0.005). (C) Temporal association of summed epitope hits of 648 six coronaviruses after symptom onset, shown for acute COVID-19 patients (n = 97) and 649 healthy controls (n = 18). Horizontal green bars represent means of healthy controls. (**D**) 650 Percentage of healthy controls and COVID-19 patients with positive results for epitopes of six 651 coronavirus species. Significantly enriched epitopes (p < 0.05) of spike and nucleocapsid are 652 indicated accordingly. (E-F) Summed hits for cross-reactive epitopes, comparing healthy 653 controls and patients with mild and severe COVID-19 (E) or COVID-19 patients with or 654 without ANA (F). (G) Percentage of ANA-positive and ANA-negative COVID-19 patients with positive results for cross-reactive and non-cross-reactive epitopes of six coronavirus 655 656 species. Dashed lines mark significance threshold at p < 0.05. (H) Percentage of ANA-positive 657 and ANA-negative study participants (n = 115) with positive results, shown for all available 658 epitopes. Significantly enriched epitopes (p < 0.005) are colored. EBV, Epstein-Barr virus; 659 HSV-2, herpes simplex virus 2; VZV, varizella-zoster virus; other, other viruses comprising 660 Aichivirus A and Mamastrovirus 1. (I) Summed epitope hits per individual including all 661 available epitopes, comparing ANA-negative and ANA-positive participants (top; n = 115), 662 and as a function of age (bottom).

#### **Figure 6. ANA-positive COVID-19 patients exhibit a pro-inflammatory signature. (A)**

PCA accounting for 130 parameters (**Table S5**) including data of healthy controls (n = 28) and 664 665 acute COVID-19 patients (n = 146). Participants with missing values were excluded from this 666 analysis. 95% confidence ellipses (t-distributed) are shown for healthy controls and severe COVID-19 patients. (**B**) Loadings (variable coordinates) of the PCA depicted in (A), with each 667 668 parameter shown as an individual dot. Colors indicate the group of COVID-19 patients with 669 higher mean for each parameter, and parameters with significant differences (p < 0.05) are 670 represented as large dots and selected parameters are annotated (Table S5). (C–E) Comparison 671 of ANA-negative and -positive individuals among healthy controls or acute COVID-19 672 patients. (C) Patient characteristics, including duration of hospitalization (n = 174) and age (n = 216). (D) Inflammation markers, including CRP (n = 209) and IL-6 (n = 215). (E) T cell 673 674 activation, including sIL-2R $\alpha$  (n = 215), and CD38<sup>+</sup>HLA-DR<sup>+</sup> CD4<sup>+</sup> (n = 210) and CD8<sup>+</sup> (n = 675 209) T cells. (F-G) PCA (F) and loadings (G) accounting for 43 parameters (Table S6) 676 including data of COVID-19 patients six months after recovery (n = 107). Participants with 677 missing values were excluded from this analysis. (H-I) Comparison of ANA-negative and ANA-positive COVID-19 patients six months after recovery. (H) Concentration of total Ig 678 subclasses in serum (n = 116). (I) Frequency of B cell subsets, including  $IgD^+CD27^-$  naïve, 679 680 IgD<sup>+</sup>CD27<sup>+</sup> non-switched memory and IgD<sup>-</sup>CD27<sup>+</sup> switched memory B cells (n = 114).

medRxiv preprint doi: https://doi.org/10.1101/2022.01.08.22268901; this version posted February 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



Α



Figure 1\_Taeschler et al.





# Figure 3\_Taeschler et al.



Figure 4\_Taeschler et al.



Figure 5\_Taeschler et al.

